DiaMedica Therapeutics Reports $10.1 Million Net Loss in Q2 2026

DiaMedica Therapeutics Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $10.1 million, compared to a loss of $7.7 million in the same period of 2025. For the six months ended June 30, 2026, the company incurred a net loss of $20.2 million, up from $15.4 million in the prior year. The increase in losses is attributed primarily to higher research and development (R&D) expenses, which rose to $8.2 million for the quarter, up from $5.8 million in 2025, and $16.1 million for the six months, compared to $11.5 million in the previous year. General and administrative expenses also saw a slight increase, totaling $2.3 million for the quarter and $4.8 million for the six months.

The company’s total assets decreased to $45.0 million as of June 30, 2026, down from $61.4 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $5.1 million from $15.6 million. Marketable securities also decreased to $38.4 million from $44.2 million. The company’s working capital was reported at $37.7 million, down from $55.5 million at the end of the previous fiscal year. As of June 30, 2026, DiaMedica had an accumulated deficit of $192.9 million since its inception.

In terms of operational developments, DiaMedica is advancing its lead product candidate, DM199, which is in clinical trials for the treatment of preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS). The company is currently conducting a Phase 2/3 trial, known as the ReMEDy2 trial, which aims to enroll approximately 300 participants across 100 sites globally. However, the company has faced challenges with slower-than-expected site activations and participant enrollment, attributed to staffing shortages in medical facilities and competition for research staff. To address these issues, DiaMedica has expanded its internal clinical team and is bringing certain trial activities in-house.

Looking ahead, DiaMedica anticipates continued operating losses as it progresses with its clinical development programs. The company expects that its current cash resources will be sufficient to fund operations for at least the next 12 months. However, it may require additional capital to support ongoing and future clinical studies, regulatory activities, and potential commercialization efforts. The company has indicated that it may seek to raise additional funds through equity or debt financing, or strategic collaborations, although there are no assurances that such funding will be available on favorable terms.